NEXI (NexImmune) Accounts Payable: $1.28 Mil (As of Jun. 2024)


What is NexImmune Accounts Payable?

NexImmune NEXI Accounts Payable is $1.28 Mil as of Jun. 2024.

NexImmune's Accounts Payable for the quarter that ended in Jun. 2024 was $1.28 Mil.

NexImmune's quarterly Accounts Payable declined from Dec. 2023 ($1.34 Mil) to Mar. 2024 ($0.77 Mil) but then increased from Mar. 2024 ($0.77 Mil) to Jun. 2024 ($1.28 Mil).

NexImmune's annual Accounts Payable increased from Dec. 2021 ($1.05 Mil) to Dec. 2022 ($2.38 Mil) but then declined from Dec. 2022 ($2.38 Mil) to Dec. 2023 ($1.34 Mil).

NexImmune Accounts Payable Historical Data

* Premium members only.

The historical data trend for NexImmune's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune Accounts Payable Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial 1.17 2.76 1.05 2.38 1.34

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.74 1.34 0.77 1.28

NexImmune Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.28 Mil mean?
NexImmune (NEXI) has a Accounts Payable of $1.28 Mil as of Jun. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on NexImmune and its competitors.
Is NexImmune's Accounts Payable too high?
NexImmune's current Accounts Payable is $1.28 Mil.
How does NexImmune's Accounts Payable compare to PPCBD and ENDV?
NexImmune's Accounts Payable of $1.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on NexImmune and its competitors. NexImmune's current Accounts Payable is $1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (NEXI) has a current Accounts Payable of $1.28 Mil. The current Accounts Payable is $1.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For NexImmune (NEXI), the current Accounts Payable is $1.28 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.